Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.83 -0.29 (-1.80%)

Streaming Delayed Price Updated: 1:29 PM EST, Feb 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

February 23, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

February 17, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 30, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

January 29, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

January 12, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

January 12, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Summit Therapeutics

Via Business Wire

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

November 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Present at Upcoming Investor Conferences

November 04, 2025

From Summit Therapeutics

Via Business Wire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

October 31, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Raises $500 Million in Private Placement

October 22, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

October 20, 2025

From Summit Therapeutics

Via Business Wire

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

October 19, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

October 17, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

October 15, 2025

From Summit Therapeutics

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 24, 2025

From Pomerantz LLP

Via GlobeNewswire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2025

From Summit Therapeutics

Via Business Wire

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

September 24, 2025

From Summit Therapeutics

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

September 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

September 03, 2025

From Summit Therapeutics

Via Business Wire

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

August 14, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

August 11, 2025

From Summit Therapeutics

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Delivering useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/pages/Cabling-Installation-and-Maintenance/298118662118

https://www.instagram.com/cim_magazine/

https://www.linkedin.com/company/3962332

http://twitter.com/CABLINGMAG

Affiliated Brands

DATA CENTER FRONTIER

ISE

LIGHTWAVE

DIGITAL INFRASTRUCTURE GROUP

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions